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The Evolving Pharmaceutical Industry
For decades, the pharmaceutical industry was
lauded for its role in improving the health of
the world’s population. However, the industry
has faced significant challenges in recent years.
Its pipeline of new products has weakened, and
costs for research and development, sales, and
marketing have increased. Other issues—such as
increased scrutiny of pharmaceutical practices,
concern over the high cost of pharmaceuticals,
and litigation related to several high-profile
drug safety recalls—have served to tarnish
the industry’s reputation. This combination of
factors has forced the industry to reassess how
it conducts business. This article will explore a
few of the ways pharmaceutical companies are
attempting to operate more efficiently and work
to repair their image and regain public trust.
There has been considerable progress on the
front to increase transparency regarding business
practices. In March 2008, AstraZeneca announced
that it would begin posting online a list of all
contributions to state and federal political
candidates, complete with recipients’ names and
the total amount contributed.1 Two months later,
Eli Lilly issued a statement in support of the
Physicians Payments Sunshine Act, legislation
sponsored by Senators Charles Grassley (R-Iowa)
and Herbert Kohl (D-Wisconsin) to create a
national registry of all payments over $500 made
to physicians by pharmaceutical companies,
medical device, and medical supply companies.
Lilly announced it would begin voluntarily
reporting this information online in 2009.2
Merck, in September 2008, pledged to disclose
physician payments for speaking engagements
beginning in 2009.3
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Pfizer also made significant strides to reduce
potential conflicts of interest. In July 2008 it
announced that the company would no longer
directly support Continuing Medical Education
(CME) courses offered by for-profit medical
education and communication companies.4
This action attempts to ensure that CME
courses remain focused on improving clinical
care and patient outcomes, and are not
mistaken for promotional programs.
Given the current difficult economic environment,
many firms are turning to mergers and layoffs
to improve efficiency and lower operating costs.
High-profile mergers, such as the Eli Lilly and
ImClone merger completed in November 2008,5
can serve to expand a company’s pipeline of future
medications and help to re-focus their efforts
on innovative therapies instead of relying on
“me-too” and patent-extending reformulations
of existing medications. Wyeth, Merck and
several other companies have, in recent months,
announced workforce reductions of greater than
ten percent.6 This reduction in the workforce
poses many questions for the future, and it is too
early to tell if it will also impact the progress of
research and development.

of America (PhRMA). The most recent voluntary
guidelines on direct-to-consumer (DTC)
advertising, issued in December 2008, call for an
end to off-label promotion in DTC advertising,
and ask manufacturers to define risks as clearly
as they define benefits in commercials and
print ads.8 While these guidelines do nothing to
address the sheer volume of advertising aimed
at consumers, and are merely voluntary, they
do address some key concerns that have been
voiced by critics.
The changes occurring in the pharmaceutical
industry certainly show an attempt to repair an
image that has been tarnished in recent years
by safety recalls, criminal fines, and compliance
failures. The industry will need to continue to
transform itself and focus on its core mission; to
develop novel, innovative products that improve
the lives of patients around the world 
Joe Couto, PharmD, MBA
Pharmacoeconomics and Outcomes
Research Fellow
Jefferson School of Population Health
For more information contact the author at:
joseph.couto@jefferson.edu.

A recent survey of industry stakeholders found
that an astounding 94% of respondents believe
that pharmaceutical companies spend too
much on advertising.7 Reversing this belief is
imperative to improving the current public
perception of the industry. The industry is
attempting to shed this image by regulating
itself through guidelines set forth by the
Pharmaceutical Research and Manufacturers
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